Risk of Arterial and Venous Thromboembolic Events with Bevacizumab, an Antibody against Vascular Endothelial Growth Factor A (VEGF-A): A Systematic Review and Meta-Analysis. GJMR. 2020;20(B1):71-85. Accessed August 13, 2026. https://medicalresearchjournal.org/index.php/GJMR/article/view/1952